Daily MaverickANC cannot renew itself by looking inwards while voters turn awayThe Jerusalem PostMichigan Jews question Sen. Elissa Slotkin over her support for El-Sayed in US midterm electionBollywood HungamaAmitabh Bachchan, Abhishek Bachchan receive death threats from gangster Goldy Dhillon; claims 200 associates are active in MumbaiThe Hollywood ReporterIVE, BINI, KiiiKiii, SB19, LiSA and Babymetal Score Grammy Nominations in New Asian Pop CategoryZDF heuteAktuelle Pressemitteilungen des ZDFIl Fatto QuotidianoGrammy Nomination 2027: Raye in testa con 11 candidature, segue Rosalía con 9. Madonna torna in pista dopo 16 anni. Harry Styles e Bad Bunny snobbati20 MinutenRadikale Winzer lassen Sprengsatz in Weinhandelsfirma detonierenThe Sydney Morning HeraldRobert Pattinson cast as next James BondVanguardLagos retrains sanitation workers on safety, efficiencyWirtualna PolskaRozmowy w Belwederze ws. TK. Bogucki mówi o sukcesieGlobal NewsBank of Canada’s Tiff Macklem won’t seek a 2nd term as governorSouth China Morning PostUK media regulator tightens curbs on online child abuse material
The Daily Newsstand · Free, Always
Monday, November 16, 2026

Boots to prescribe medical cannabis in first for high street pharmacy

Translate

Boots is set to start prescribing medical cannabis to people living with certain conditions.

In a first for a high street pharmacy, the chain is offering its new private specialist service, Sure Leaf, to patients living with chronic pain, anxiety, and insomnia who are older than 24.

Patients are required to have tried conventional treatments without achieving symptom relief, and proposed prescriptions will be independently reviewed by a clinical team.

Dr David Gwynne, the medical director at Boots Online Doctor, said: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.

“SureLeaf has therefore been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate.

“Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.”

SureLeaf was launched by Boots on Monday

SureLeaf was launched by Boots on Monday (Boots)

The service is being launched alongside a collaborative research programme with the University of Nottingham that will examine the outcomes for patients who have been prescribed medical cannabis for chronic pain.

Patients with an eligible condition will first be assessed online before progressing to a video consultation with someone on the General Medical Council Specialist Register.

If successful, they will then receive ongoing clinical support and monitoring alongside treatment to help determine its effectiveness.

The UK legalised medical cannabis in 2018, and while a small number of patients can obtain the drug on the NHS, most products are prescribed by private clinics.

Nearly two million unlicensed cannabis items were prescribed privately in England between June 2025 and May this year.

It has sparked warnings over potential risks to patients and calls for new measures to safeguard people purchasing medical cannabis on online platforms.

Jamie Kerruish, chief healthcare officer for Boots, said: “At Boots, we’re committed to making healthcare more accessible and helping people find the right support for their individual needs. Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief.

“This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy. Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care.

“Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.”

Chronic pain conditions that warrant a prescription include chronic primary and neuropathic pain, fibromyalgia, complex regional pain syndrome, chronic back or neck pain, osteoarthritis, rheumatoid arthritis, sciatica, peripheral neuropathy, trigeminal neuralgia, phantom limb pain, chronic migraine, endometriosis-related pelvic pain and chronic abdominal or pancreatic pain.

Patients with generalised anxiety disorder and insomnia disorder are also eligible.

View the original on The Independent →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.